Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E White

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1994
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2D J Schwartzentruber, S S Hom, R Dadmarz, et al.
Cancer|February 15, 1995
The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinomaM P MacFarlane, J C Yang, A S Guleria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1985
Patterns of recurrence in patients with high-grade soft-tissue sarcomasD A Potter, J Glenn, T Kinsella, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1995
HLA associations in the antitumor response against malignant melanomaF M Marincola, P Shamamian, L Rivoltini, et al.
Cancer|July 1, 1986
High-grade soft tissue sarcomas of the extremitiesD A Potter, T Kinsella, E Glatstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1989
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancerS A Rosenberg, M T Lotze, J C Yang, et al.
Surgery|December 1, 1992
A randomized, prospective trial of postoperative somatostatin analogue in patients with neuroendocrine tumors of the pancreasJ R Lange, S M Steinberg, G M Doherty, et al.
JAMA|March 23, 1994
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2S A Rosenberg, J C Yang, S L Topalian, et al.
Cancer|August 15, 1995
The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2J C Yang, S L Topalian, D J Schwartzentruber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1989
Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patientsB Fisher, A M Keenan, B S Garra, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1994
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2D J Schwartzentruber, S S Hom, R Dadmarz, et al.
Cancer|February 15, 1995
The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinomaM P MacFarlane, J C Yang, A S Guleria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1985
Patterns of recurrence in patients with high-grade soft-tissue sarcomasD A Potter, J Glenn, T Kinsella, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1995
HLA associations in the antitumor response against malignant melanomaF M Marincola, P Shamamian, L Rivoltini, et al.
Cancer|July 1, 1986
High-grade soft tissue sarcomas of the extremitiesD A Potter, T Kinsella, E Glatstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1989
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancerS A Rosenberg, M T Lotze, J C Yang, et al.
Surgery|December 1, 1992
A randomized, prospective trial of postoperative somatostatin analogue in patients with neuroendocrine tumors of the pancreasJ R Lange, S M Steinberg, G M Doherty, et al.
JAMA|March 23, 1994
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2S A Rosenberg, J C Yang, S L Topalian, et al.
Cancer|August 15, 1995
The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2J C Yang, S L Topalian, D J Schwartzentruber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1989
Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patientsB Fisher, A M Keenan, B S Garra, et al.
Pageof 7